Efficacy News and Research

RSS
FDA accepts Labopharm's response for its novel trazodone formulation

FDA accepts Labopharm's response for its novel trazodone formulation

Glaxosmithkline affirms safety of Alli

Glaxosmithkline affirms safety of Alli

FDA approves Supersonic Imagine's Aixplorer ultrasound system

FDA approves Supersonic Imagine's Aixplorer ultrasound system

Alvine Pharmaceuticals commences Phase 2a clinical trial to evaluate the efficacy of ALV003

Alvine Pharmaceuticals commences Phase 2a clinical trial to evaluate the efficacy of ALV003

University of Maryland researchers perform a  genome-wide association study of ADP-stimulated platelet aggregation

University of Maryland researchers perform a genome-wide association study of ADP-stimulated platelet aggregation

Free webinar for business travel industry on swine flu pandemic

Free webinar for business travel industry on swine flu pandemic

Cybex International re-brands its research division as Cybex Institute For Exercise Science

Cybex International re-brands its research division as Cybex Institute For Exercise Science

Seattle Genetics completes enrollment of its pivotal clinical trial of brentuximab vedotin

Seattle Genetics completes enrollment of its pivotal clinical trial of brentuximab vedotin

Neurogen stockholders to receive $11 million in Ligand Pharmaceuticals common stock as part of acquisition deal

Neurogen stockholders to receive $11 million in Ligand Pharmaceuticals common stock as part of acquisition deal

UCB and sanofi-aventis U.S. receive FDA's approval for XYZAL to treat allergies in children

UCB and sanofi-aventis U.S. receive FDA's approval for XYZAL to treat allergies in children

Bioniche Life Sciences update on Phase III clinical program for evaluating Urocidin

Bioniche Life Sciences update on Phase III clinical program for evaluating Urocidin

Retigabine's Phase IIa clinical trial preliminary results announced

Retigabine's Phase IIa clinical trial preliminary results announced

Bioelectronics to sponsor clinical study comparing the effects of ActiPatch to Tylenol for the treatment of muscle pain and soreness

Bioelectronics to sponsor clinical study comparing the effects of ActiPatch to Tylenol for the treatment of muscle pain and soreness

CSL Biotherapies initiates clinical trials of Influenza A/H1N1 2009 vaccine in the US

CSL Biotherapies initiates clinical trials of Influenza A/H1N1 2009 vaccine in the US

Phase 2 clinical study of Resolvin RX-10045 for dry eye syndrome provides positive data

Phase 2 clinical study of Resolvin RX-10045 for dry eye syndrome provides positive data

Study reveals that increased neurostimulation market offers growth for device industries

Study reveals that increased neurostimulation market offers growth for device industries

Prescient Medical's vProtect(TM) Luminal Shield Stent System receives CE Mark approval for treating heart disorders

Prescient Medical's vProtect(TM) Luminal Shield Stent System receives CE Mark approval for treating heart disorders

NovaBay Pharmaceuticals to deliver two poster presentations describing results from new studies of NVC-422

NovaBay Pharmaceuticals to deliver two poster presentations describing results from new studies of NVC-422

Microbiologists discover new therapies for human respiratory syncytial virus and influenza A virus

Microbiologists discover new therapies for human respiratory syncytial virus and influenza A virus

Discovery of genetic biomarkers enable targeted personalised medication for Colorectal cancer

Discovery of genetic biomarkers enable targeted personalised medication for Colorectal cancer

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.